About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label
Scientific Clinical | AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
17 April 2018
Scientific Clinical | Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
3 May 2018
Financial | NANOBIOTIX selected to enter Euronext’s Tech 40 Label
Published by
adminvl
on
26 April 2018
No translations available for this page
